The aim of this study is to establish diagnostic and predictive biomarkers for patients with suspected acute stroke, that are transported by EMS as candidates for thrombolytic treatment. The study focuses on the ultra acute phase, <4.5 hours from symptom onset, including the prehospital setting. Analyses will include known biomarkers (e.g. GFAP, NR2 peptide) and a discovery phase for novel markers. Patient outcome will be evaluated at 3 month using the modified Rankin Scale (mRS).
- Observation: Case-Only
- Perspective: Prospective
- Sampling: Probability Sample
Patients with suspected acute stroke, being transported by emergency medical services (EMS) to a tertiary hospital stroke center, as candidates for thrombolytic treatment of acute ischemic stroke.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Diagnostic accuracy of biomarkers for identifying ischemic stroke, transient ischemic attack, intracerebral hemorrhage and stroke mimics.||90 days +/- 5 days||No|
|Primary||Predictive accuracy of biomarkers for identifying patients not responding to thrombolytic treatment.||90 days +/- 5 days||No|
|Primary||Predictive accuracy of biomarkers for identifying patients facing hemorrhagic complications of thrombolytic treatment||90 days +/- 5 days||No|
|Primary||Predictive accuracy of biomarkers for predicting outcome||90 days +/- 5 days||No|
Biospecimen Retention:Samples Without DNA - Human Serum and Plasma